Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). The firm’s ongoing investigation concerns whether Zymeworks and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On April 1, 2024, Zymeworks disclosed that it had removed Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, effective immediately. Although Zymeworks indicated that it had appointed current President and Chief Executive Officer Kenneth Galbraith as Interim CFO and had initiated a search for a new CFO, the Company failed to provide any reasoning for Astle’s removal as SVP and CFO. On this news, the price of Zymeworks shares declined by $0.64 per share, or approximately 6.08%, from $10.52 on March 28, 2024 to close at $9.88 per share on April 1, 2024.

If you purchased or otherwise acquired Zymeworks securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at [e-mail], or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.